Overview

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

Phase I, open label, single arm, non-randomized, multicenter, prospective dose escalation study in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT).

Phase:

Phase 1

Details

Lead Sponsor:

Philogen S.p.A.

Collaborator:

Boehringer Ingelheim

Treatments:

Interleukin-2